Health Condition 1: H32- Chorioretinal disorders in diseases classified elsewhere
Conditions
Interventions
Intervention1: inj intravitreal anti VEGF ranibizumab and inj suprachoroidal triamcenolone acetonide: Single injection of 0.05 ml ranibizumab will be given intravitreally and 0.1 ml of triamcinolone w
Sponsors
GSVM MEDICAL COLLEGE
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed patients of Wet ARMD on FFA and OCT pattients giving consent and willing for follow up
Exclusion criteria
Exclusion criteria: Patients with raised RBS levels (more than 200mg/dl). Patients with any ocular infection, raised Intraocular pressure (IOP), any corneal pathology, thinned sclera, scleritis, staphyloma, or any other anterior segment pathology except Pseudophakic patients. Patients diagnosed of any other retinal or vitreous pathologies except wet ARMD.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early resolution of choroidal neovascular tissue Early and sustained improvement in Best Corrected Visual Acuity (BCVA)Timepoint: Baseline, 7th day, 15th day, 1 month, 2nd month, 3rd month | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Garima Singh
GSVM Medical College Kanpur
Outcome results
None listed